AS
Publicaties op Oncologisch.com
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ...
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
Venetoclax bij recidief/refractaire CLL: MURANO/CLL14 analyse
Acalabrutinib met of zonder obinutuzumab versus chlorambucil-obinutuzumab bij onbehandelde CLL: ELEVATE-TN fase III